Bridgeway Capital Management’s Caribou Biosciences CRBU Stock Holding History

Bridgeway Capital Management’s Portfolio CRBU Stock Details CRBU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$251K	Sell	132,000 -16,500	-11%	-$28.3K	0.01%	979
2025 Q4	$236K	Hold	148,500	–	–	﹤0.01%	988
2025 Q3	$346K	Hold	148,500	–	–	0.01%	886
2025 Q2	$187K	Buy	148,500 +40,000	+37%	+$39.3K	﹤0.01%	975
2025 Q1	$99.1K	Sell	108,500 -97,400	-47%	-$127K	﹤0.01%	1037
2024 Q4	$327K	Sell	205,900 -28,501	-12%	-$57.3K	0.01%	903
2024 Q3	$459K	Buy	+234,401	New	+$480K	0.01%	882

Other funds holding CRBU

Pfizer New York $239M AUM 232.47% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Bridgeway Capital Management's CRBU Position: Q1 2026 in Review

Bridgeway Capital Management reduced its Caribou Biosciences (CRBU) stake by 11% in Q1 2026, selling an estimated $28.3K and leaving 132,000 shares worth $251K. The position accounts for 0.01% of the portfolio, ranked #979.

Bridgeway Capital Management first reported a position in CRBU in Q3 2024 and has held it in 7 quarters since. The position peaked at $459K in Q3 2024. 137 funds tracked by Wall St. Rank hold CRBU as of Q1 2026.

Bridgeway Capital Management held 132,000 shares of Caribou Biosciences worth $251K as of Q1 2026.
Bridgeway Capital Management sold 16,500 Caribou Biosciences shares in Q1 2026, an estimated $28.3K.
Caribou Biosciences made up 0.01% of Bridgeway Capital Management's portfolio in Q1 2026, its #979 holding.
Bridgeway Capital Management first reported a position in Caribou Biosciences in Q3 2024 and has held it in 7 quarters since.
Bridgeway Capital Management's Caribou Biosciences position peaked at $459K in Q3 2024.
137 funds tracked by Wall St. Rank held Caribou Biosciences as of Q1 2026.

Based on Bridgeway Capital Management's 13F filing for Q1 2026, filed 15 May 2026.